Bicycle Therapeutics(BCYC) - 2025 Q2 - Quarterly Results

Exhibit 99.1 Bicycle Therapeutics Reports Recent Business Progress and Second Quarter 2025 Financial Results Continued advancement across research and development pipeline, with key program updates expected in 2H 2025 Phase 1/2 Duravelo-4 trial for zelenectide pevedotin in NECTIN4-amplified non-small cell lung cancer open and actively recruiting patients Strengthened clinical leadership and bolstered roster of scientific advisors with additions to Board of Directors and creation of Research and Innovation A ...